2.4
[]. Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D and D2 receptors. Eur J Pharmacol. 206 Oct 5;88:8-9.
[2]. Radad K, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP+ and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 204;52(2):9-86.
[]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 209 Feb;5(2):2-246.
[4]. Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;9():-86.
[5]. Wood M, et al. Rotigotine is a potent agonist at dopamine D receptors as well as at dopamine D2 and D receptors. Br J Pharmacol. 205 Feb;2(4):24-5.
H02-H5-H9-H5
P26-P264-P20-P2-P280-P02+P52-P04+P40-P05+P5+P8-P0-P62+P64-P40+P2-P405-P50
GHS0
![]()
![]()